Form 4: Janux Therapeutics VP of Accounting Receives Stock Options and Restricted Stock Units

Maria Dobek, Vice President of Accounting at Janux Therapeutics, was granted stock options and restricted stock units, increasing her beneficial ownership in the company.

Summary

• Maria Dobek, the Vice President of Accounting at Janux Therapeutics, received 14,000 restricted stock units (RSUs) and options to purchase 31,500 shares of common stock on January 2, 2025.
• The RSUs vest in four equal annual installments starting January 1, 2026.
• The stock options vest 25% on January 1, 2026, and the remaining balance vests in equal monthly installments over the following three years.
• Ms. Dobek also acquired 1 share of common stock through the company's Employee Stock Purchase Plan on November 15, 2024.
• Following these transactions, Ms. Dobek's total beneficial ownership includes 14,001 shares of common stock and options for 31,500 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management and shareholder interests. There are no negative aspects to the document.

Positives

• The grant of RSUs and stock options to a key executive aligns her interests with the long-term success of the company.
• The vesting schedule of the RSUs and stock options encourages long-term commitment from the executive.
• The employee stock purchase plan allows employees to acquire shares in the company.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a long-term incentive structure for the executive.

Industry Context

This type of equity compensation is common practice for publicly traded companies to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based incentives to align executive interests with shareholder value.
• The vesting schedules described are typical, with vesting periods ranging from 3 to 5 years, often with a cliff vesting period of one year.

Stakeholder Impact

• The equity grants align the executive's interests with those of shareholders, encouraging long-term value creation.
• The vesting schedule may encourage the executive to remain with the company for the long term.

Key Dates

Keywords

stock options, restricted stock units, RSUs, insider trading, beneficial ownership, executive compensation, Janux Therapeutics, equity compensation